• Search
  • Advanced Search

Search

  • HOME
  • Search
Review Article
Infection
Updates on the coronavirus disease 2019 vaccine and consideration in children
Hyun Mi Kang, Eun Hwa Choi, Yae-Jean Kim
Clin Exp Pediatr. 2021;64(7):328-338.   Published online June 21, 2021
· The number of coronavirus disease 2019 cases has exponentially increased worldwide, and children ≤19 years old account for 11.0% of all confirmed cases.
· mRNA vaccines, BNT162b2 and mRNA-1273, and adenoviral vector vaccines, AZD1222 and Ad26.COV2.S, authorized for emergency use in the Emergency Use Listing of the World Health Organization are reviewed.
· Clinical trials of these vaccines have shown that they are safe and serious adverse reactions are rarely observed.
Original Article
Immunology
Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6–10 weeks: a randomized double-blind active-controlled trial
Jonghoon Shin, Jamaree Teeratakulpisarn, Thanyawee Puthanakit, Tuangtip Theerawit, Ji Hwa Ryu, Jinhwan Shin, Seulgi Lee, Hayoung Lee, Kyungjun An, Hun Kim
Clin Exp Pediatr. 2020;63(7):265-271.   Published online December 6, 2019
Question: The immunogenicity and safety of GBP411 when administered to healthy infants are not understood.
Finding: The intergroup differences were not significant for all 12 serotypes after the booster dose. The overall incidence of solicited local adverse events between the groups did not differ significantly.
Meaning: GBP411 with a 2p+1 dosing schedule induced a substantial immune response, and may be safe for administration to healthy infants.
Immunogenicity and safety of enhanced-inactivated poliovaccine(eIPV) in healthy Korean infants
Jung Soo Kim, Young Jin Hong, Jong Duk Kim, Young Taek Jang, Jin Han Kang
Clin Exp Pediatr. 2006;49(8):864-869.   Published online August 15, 2006
Purpose : We evaluated the immunogenicity and safety of eIPV(Imovax PolioⓇ) in a group of healthy Korean infants on a three-dose primary vaccination. Methods : Eighty one healthy infants aged 8-10 weeks were enrolled, and 79(male 42, female 37) completed the study. Three doses of eIPV were injected intramuscularly at 2, 4 and 6 months of age as of primary...
The Safety and Immunogenicity of a Trivalent, Live, Attenuated MMR Vaccine, PriorixTM
Seung-In Ahn, Min-Kook Chung, Jung-Suk Yoo, Hye-Jeon Chung, Jae-Kyun Hur, Young-Kyu Shin, Jin-Keun Chang, Sung-Ho Cha
Clin Exp Pediatr. 2005;48(9):960-968.   Published online September 15, 2005
Purpose : This multi-center, open-label, clinical study was designed to evaluate the safety and immunogenicity of a trivalent, live, attenuated measles-mumps-rubella(MMR) vaccine, PriorixTM in Korean children. Methods : From July 2002 to February 2003, a total of 252 children, aged 12-15 months or 4-6 years, received PriorixTM at four centers : Han-il General Hospital, Kyunghee University Hospital, St. Paul's Hospital at...
Immunogenicity and Safety of Live Attenuated Vaccine(MAV/06srtain) on Healthy Children and Immunocompromised Children
Young Mo Sohn, Chul Joo Yu, Pyung Kil Kim, Kir Young Kim, Chong Young Park, Mi Ran Kim, Woo Kap Jeung, Kyu Kye Hwang, Gyu Jin Woo, Song Yong Park
Clin Exp Pediatr. 1995;38(6):771-777.   Published online June 15, 1995
Purpose : To study the safety and immunogenicity of new live attenuated varicella vaccine (MAV/06strain) in normal healthy children and immunocompromized children in Korea. Methods : Blood samples for fluorescent antibody to membrane antigen(FAMA) assay were taken before the vaccination among seven hundred forth five healthy children and twenty two nine immunocompromised children. One hundred and seventy seven children and twenty...
Safety and Immunogenicity of Live Attenuated Varicella Virus Vaccine(MAV/06 strain)
Young Mo Sohn, Chong Young Park, Kyu Kye Hwang, Gyu Jin Woo, Song Yong Park
Clin Exp Pediatr. 1994;37(10):1405-1413.   Published online October 15, 1994